Medical Verification: Data referenced from Dexrevo Biotechnology In-Vivo Clinical Trial (Study ID: DX-2022-BR). Medically reviewed for clinical accuracy by Board-Certified Dermatologists.

Target Plane: Mid-to-deep dermis junction (1.5mm – 2.0mm depth).

Volume Allocation: 0.1ml to 0.2ml per injection site. Maximum 2.0ml cumulative volume per facial session.

Delivery Mechanism: Standard 30G to 32G hypodermic needle, or 27G blunt-tip micro-cannula for broad vectoring.

Treatment Interval: Primary phase requires 3 distinct sessions spaced precisely 4 weeks apart. Maintenance phase requires single application biannually.

Shelf Life & Storage: 5 vials × 5.0ml per sterile unit. Viable for 24 months stored strictly at 2°C – 8°C.

Restricted Distribution: Miracle Touch BR contains highly concentrated medical-grade compounds. Sale and administration are strictly restricted to board-certified dermatologists, plastic surgeons, and licensed aesthetic practitioners.

Absolute Contraindications: Administration is strictly prohibited in patients exhibiting active autoimmune dermatoses, localized dermal infections (bacterial or viral), hypersensitivity to Vitamin C or PCL polymers, and individuals currently pregnant or lactating.

Expected Adverse Events: Clinical trials indicate potential for transient erythema, pinpoint ecchymosis, and localized edema resolving spontaneously within 48 to 72 hours post-administration. A mandatory 48-hour dermal patch test is required prior to full protocol execution.